
Search
Filter Results
Displaying 51–60 of 705 for “retinitis clinical trial”
-
Mar 30, 2023
Most participants with advanced retinitis pigmentosa (RP) in the trial had improved navigation and/or object discrimination in reduced lighting conditions
-
May 3, 2021
ARVO 2021 Highlight: Update on Clinical Trial of jCyte’s Cellular Therapy for RP
Cellular treatment provided significant improvements in visual acuity for subpopulation of patients with better vision
-
Jul 27, 2020
jCyte Reports Promising Results for Phase 2b Clinical Trial of its Cellular Therapy for RP
The emerging therapy is designed to work independent of the mutated gene causing vision loss
-
Jun 5, 2024
Antabuse Moves into Clinical Trial for People with RP
Researchers believe the FDA-approved drug can reduce the hyperactivity of ganglion cells to improve vision.
-
Jul 12, 2023
PYC Doses First Patient in Clinical Trial of RNA Therapy for RP11 (PRPF31 Mutations)
The emerging RNA therapy is designed to boost expression of the PRPF31 protein
-
Dec 7, 2018
FDA Authorizes Clinical Trial for CRISPR/Cas9 Therapy for LCA 10
Editas Medicine, a company developing gene-editing treatments, has received authorization from the US Food and Drug Administration to launch a clinical trial for its emerging CRISPR/Cas9 therapy for people with a mutation in the gene CEP290, which causes Leber congenital amaurosis 10 (LCA10). LCA causes severe vision loss or blindness at birth.
-
Apr 1, 2020
Interim Results Released for USH2A RNA Therapy Clinical Trial
Suggestions of efficacy observed in 25 percent of participants receiving the treatment
-
Apr 11, 2024
ViGeneron Launches Clinical Trial of Gene Therapy for RP Caused by CNGA1 Mutations
The gene therapy is administered using a less-invasive intravitreal injection.
-
Apr 8, 2024
Ocugen to Launch Phase 3 Clinical Trial of Modifier Gene Therapy for RP
The emerging treatment is designed to work independent of the patient’s mutated gene.
-
Jul 14, 2022
Endogena Launches Clinical Trial of Therapy to Activate Stem Cells in RP Patients’ Retinas
The emerging treatment is gene-agnostic.